Clinical trials: Epicardial Adipose Tissue
Type 2 Diabetes, Overweight
Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes
The purpose of this research study is to learn about the effect of Liraglutide, (Victoza®), on the fat surrounding the heart.Excessive amount of the fat around the heart is common in people with type 2 diabetes and can be…
- Conditions
- Type 2 Diabetes, Overweight, Obesity
- Trial name
- NCT02014740
- Testing
- Liraglutide, Metformin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Miami
Type 2 Diabetes
Dapagliflozin Effects on Epicardial Fat
The purpose of this research study is to learn about the effect of Dapagliflozin (Farxiga) on the fat of the heart.
- Trial name
- NCT02235298
- Testing
- Dapagliflozin, Metformin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Miami
Type2 Diabetes, Coronary Artery Disease
Liraglutide Effects on Epicardial Fat Inflammatory Genes
Epicardial adipose tissue (EAT) is the visceral fat of the heart. EAT could locally affect the coronary arteries through local secretion of pro-inflammatory cytokines.
- Trial name
- NCT03260881
- Testing
- Liraglutide Pen Injector [Victoza]
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Miami
Cardiovascular Diseases, Atherosclerosis
Ertugliflozin: Cardioprotective Effects on Epicardial Fat
The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased…
- Conditions
- Cardiovascular Diseases, Atherosclerosis, Type 2 Diabetes, Insulin Resistance
- Trial name
- NCT04167761
- Testing
- Ertugliflozin
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Stanford University
Post-Operative Atrial Fibrillation
Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)
This was a multi-center, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to evaluate the efficacy and safety of botulinum toxin type A (AGN-151607) injections into the epicardial fat pads, foci of…
- Trial name
- NCT03779841
- Testing
- AGN-151607
- Where
- 32 sites in United States, Austria and 7 more
- Volunteers
- 323 people
- Sponsor
- AbbVie